FULGENT GENETICS, INC. Equity Securities, FV-NI, Unrealized Loss
FULGENT GENETICS, INC. (FLGT) reported Equity Securities, FV-NI, Unrealized Loss of $89.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2021-03-08
- FULGENT GENETICS, INC. equity securities, fv-ni, unrealized loss for fiscal 2020 was $89.00K.
| Period end | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|
| 2020-12-31 | $89.00K 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |